MAP2K7 and non-small cell lung carcinoma: Overall, this study represents a comprehensive attempt from preclinical studies to clinical studies in the development of a potential therapeutic strategy through the coinhibition of MEK/RTK pathways in NSCLC patients harboring KRAS mutations.